CYTR: CytRx Corporation - Summary | Jitta

CytRx Corporation

NASDAQ:CYTR

Notice
Stock data is unavailable or the company’s delisted.
Price
$0.61
Loss Chance
54.3%
2.43JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (30)
Recent Business Performance (40)
Financial Strength (0)
Return to Shareholders (0)
Competitive Advantage (0)
Jitta Signs
Revenue and EarningEarning loss detected in 2018
Operating MarginDeclined
Recent Business PerformanceEarning decline 63.66% in the last year
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
2.42
100.00%
2.21
139.10%
Biotechnology
6.24
38.98%
0.01
100.00%
5.83
12.58%
COMPANY DESCRIPTION
CytRx Corporation, a biopharmaceutical company, engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company’s lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides albumin companion diagnostic for cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.